Sangamo Biosciences (NASDAQ: SGMO) reported Q4 EPS of ($0.14), $0.11 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $8.9 million versus the consensus estimate of $3.91 million.

For earnings history and earnings-related data on Sangamo Biosciences (SGMO) click here.